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Abstract 
Background: It is well documented that the modelling of health related quality of life 
(HRQoL) data is difficult as the distribution of such data is often strongly right/left 
skewed and it includes a significant percentage of observations at one. Objectives: To 
develop a series of two-part models (TPM) that deal with these issues. Methods: Data 
from the UK Medical Research Council (MRC) Myeloma IX trial were used to examine 
the relationship between the European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30/QLQ-MY20 scores and the European QoL-5 Dimensions 
(EQ-5D) utility score. Four different TPM models were developed. The models fitted 
included TPM with normal regression, TPM with normal regression with variance a 
function of participant characteristics, TPM with log-transformed data and TPM with 
gamma regression and a log link. The cohort of 1839 patients was divided into 75% 
derivation sample, to fit the different models, and 25% validation sample to assess the 
predictive ability of these models by comparing predicted and observed mean EQ-5D 
scores in the validation set, unadjusted R2 and Root Mean square Error (RMSE). 
Results: Predictive performance in the derivation dataset depended on the criterion 
used, with R2/adjusted-R2 favouring the TPM model with normal regression and mean 
predicted error favouring the TPM model with gamma regression. The TPM model with 
gamma regression performs best within the validation dataset under all criteria. 
Conclusions: TPM regression models provide flexible approaches to estimate mean 
EQ-5D utility weights from the EORTC QLQ-C30/QLQ-MY20 for use in economic 
evaluation. 
 
Key words: Bayesian methods; EQ-5D; Multiple Myeloma; Quality of Life; two-part 
models; Cost-utility analysis; MCMC. 
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1. Introduction 
 
Preference-based measures of health related quality of life (HRQoL) are widely used 
to calculate quality adjusted life years (QALYs) for use in cost effectiveness analyses. 
Examples of these are the European QoL-5 Dimensions (EQ-5D) questionnaire [1], the 
six-dimensional health state short form (SF-6D) [2] and Health Utility Index 2 (HUI-
II) [3] instruments. QALYs are formed as a weighted sum of life expectancy, where 
each year is weighted on a HRQoL scale that reflect the sacrifices that people would 
make to attain or avoid the particular states in those years.  In such measures, zero and 
one are assigned specific meanings.  At a HRQoL value of one, a person would not 
PDNHDQ\VDFULILFHVIRUEHWWHUKHDOWKDQGWKH\DUHVDLGWREHLQµIXOOKHDOWK¶,QFRQWUDVW
WKRVHZLWKD+54R/YDOXHRI]HURRFFXS\DVWDWHµDVEDGDVGHDG¶, in the sense that they 
would swap a 100% certainty of death for remaining in that state; once dead, a HRQoL 
value of zero is also assigned.   
 
As a HRQoL value of one represents the state where a person no longer sacrifices to 
obtain better health, HRQoL does not usually exceed one and often has a noticeable 
µVSLNH¶KHUH$Vmost people are only willing to make moderate sacrifices for health, 
HRQoL values lie tend to at the higher end of the measurement scale, with some 
observations displaying extremely low levels of HRQoL. In principle, there is no lower 
bound to a HRQoL value, so that support may include large negative values.  Thus, 
HRQoL values often have a noticeable density spike at one and a negatively-skewed 
distribution.  In contrast the disutility of a health state (formed as one minus the HRQoL 
value), has a significant percentage of zero-disutility values and is positively skewed.  
The disutility of a particular health state therefore shares the same characteristics as 
cost data, including heteroskedasticity. 
 
Most studies modelling HRQoL data use linear regression assuming normal and 
homooscedastic error terms [4-6]. The latter condition is unlikely to be satisfied for 
bounded variables for mean values close to bounds [7]. Alternative regression methods 
that model HRQoL data include censored least absolute deviation (CLAD) models [8, 
9], Tobit models [8, 10] and median regression [9]. Of these, CLAD and Tobit methods 
model an underlying latent variable, which is censored at one. Such models are not 
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necessarily appropriate for HRQoL data because preferences are measured on a scale 
where values cannot be over  µQR +54R/ GHILFLW¶ [8]. Median regression also 
addresses the non-normality of the data [11]. However, the regression usually 
concentrates on the mean rather than the median when HRQoL data are regressed on 
individual covariates to predict QALYs [8-10].  
 
One approach advocated to address the problem generated by zero/one HRQoL 
observations is to apply a two-part model (TPM) [12-15] on disutility. Such an 
approach fits two separate models. Firstly, a logistic regression model is used to predict 
whether patients indicate any HRQoL deficit. Secondly, for those individuals who 
indicate nonzero disutility, a regression model is fitted to estimate the magnitude of the 
deficit. This approach is broadly similar to existing approaches dealing with cost data.  
For example, Cooper et al [13] have proposed a Bayesian TPM in which a logistic 
regression model was used first to predict the conditional probability of observing zero 
costs in the sample, followed by a linear regression model fitted to the log-transformed 
cost applied to those individuals reporting positive costs. This paper, and similar 
approaches elsewhere [16-17] provide flexible approaches to regress the mean of an 
outcome with truncated support such as HRQoL on covariates 
 
This paper focuses on the application of four different TPM specifications of increasing 
complexity to predict HRQoL utility in myeloma patients. The paper is organised with 
the next section describing the motivating data for the models described herein. Then 
Section 3 outlines the models used for the analysis including assessment of model 
complexity, model fit and assessment of model prediction. Section 4 illustrates the 
application of the proposed method to the analysis of HRQoL data from the case study 
presented in Section 2. Finally, the implications of the results and directions for future 
research conclude the paper. 
 
2. Motivating data set 
2.1 Measures 
The EuroQol 5D is recommended for use in economic evaluations by National Institute 
for Health and Care Excellence (NICE) [18], with the EQ-5D-3L [19] used here.  This 
measure classifies patients into one of 243 health states varying in five dimensions 
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DORQJVLGH DGGLWLRQDO VWDWHV IRU µGHDG¶ DQG µXQFRQVFLRXV¶: mobility; self-care; usual 
activities; pain/ discomfort; and anxiety/depression. The levels of each dimension are 
roughly: none, moderate, and severe. The EQ-5D is of demonstrated validity and 
reliability [1, 20] and population values are available for both the UK [21] and 
elsewhere [22]. 
 
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30) is a commonly-used instrument for 
measuring general cancer quality of life. It has been translated into more than 65 
languages and is used widely internationally [23].  It covers several health domains, as 
well as cancer-specific symptoms of disease, the side effects of treatment, 
psychological distress, physical functioning, social interaction, global health, and 
quality of life. Most of the questions have a categorical response (Not at all; A little; 
Quite a bit; and Very much), with two questions relying on the use of a Visual Analogue 
Scale (VAS). The raw questionnaire responses are transformed to produce scores (0-
100) on a set of five function scales (physical, role, emotional, cognitive, and social 
functioning) and nine symptom scales, along with a scale representing global quality of 
life. Higher scores indicate better functioning and more severe symptoms on the 
functioning and symptom scales, respectively. The EORTC QLQ-C30 scale has 
undergone extensive psychometric testing [24]. 
 
The myeloma cancer module QLQ-MY20 is acceptable for use among patients varying 
in disease level and treatment modality (i.e. surgery, chemotherapy, radiotherapy and 
hormonal treatment). It should always be used as a complement to the QLQ-C30. The 
myeloma module is designed to assess the symptoms and side effects of treatment and 
their impact on everyday life [25]. The module comprises 20 questions addressing four 
domains of QoL important in myeloma: body image, diseases symptoms, treatment side 
effects and future perspective. The module was developed according to the guidelines, 
and approved after formal review. As with the EORTC QLQ-C30 questions, the QLQ-
MY20 questions have a hierarchical response with ordinal scores transformed to a 0-
100 scale and each domain analysed separately. Both QLQ-C30 and ±MY20 domain 
scores are re-transformed to 0-1 scale, and for this to allow values to mirror the overall 
potential contribution to quality of life. 
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2.2. Data source 
The EORTC QLQ-C30 and QLQ-MY20 instruments are mapped onto the EQ-5D 
instrument using data from MYELOMA-IX1 [26]. This randomized controlled trial of 
the effectiveness of new treatment regimens at both diagnosis (CVAD vs. C-Thal-Dex 
or C-Thal-Dex attenuated; sodium clodrinate vs zoledronic acid) and maintenance (no 
therapy vs thalidomide). The trial needed a sample size of 1600 patients enlisted across 
hospitals in the UK, New Zealand and South Africa over 5 years. Overall, the trial 
recruited 1839 patients, who provided a total of 3184 observations. 
 
3. Model development and validation 
In this section, we develop a series of TPMs that take into account the typical 
characteristics of HRQoL data. All models shown are implemented from a Bayesian 
perspective using Gibbs sampling MCMC methods freely available in the specialist 
software WinBUGS [27]. The WinBUGS code is available from the corresponding 
author. MCMC methods permit great flexibility in the specification of complex non-
standard models and also facilitate the computation of model complexity and fit 
statistics for non-nested models [28]. 
 
In each model, the utility weight from the EQ-5D is treated as our dependent variable. 
Our covariates were the summary scores from each of the 19 domains of the EORTC 
QLQ-C30 and QLQ-MY20, which we treated as continuous variables, in addition to 
respondent-level covariates such as age and gender. In total, then there are up to 22 
covariate parameters in our models, being a constant term, 19 EORTC dimensions, and 
up to 2 demographic covariates. 
 
The data set described in the previous section was split into a learning sample, which 
consisted of data from a 75% derivation sample of patients and was used to fit the 
different models. A validation sample was formed and consists of the remaining 
patients and was used to assess the predictive ability of the different candidate models.   
                                               
1
 http://clincancerres.aacrjournals.org/content/early/2013/08/30/1078-0432.CCR-12-3211 
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Whilst our approach selects derivation/validation by patient, for simplicity we index by 
observations (i  «, 3184).  Had missingness been defined at a patient level, this 
would have led to complete data at a point in time being removed and classified as 
KDYLQJµPLVVLQJ¶GDWDRQWKHEDVLVWKDWPLVVLQJGDWDH[LVWVDWDGLIIHUHQWWLPHSRLQW 
 
Four different TPMs of increasing complexity were fitted to the data: 
1) TPM with second part normal regression, 
2) TPM with second part normal regression with variance a function of participant 
characteristics, 
3) TPM with second part lognormal regression, and 
4) TPM with second part gamma regression with a log link. 
 
All models considered were developed ZLWKLQ D %D\HVLDQ IUDPHZRUN XVLQJ µYDJXH¶
prior distributions throughout and implemented in the freely available WinBUGS 
software [27]. In this application, Bayesian methods provided a useful tool for fitting 
complex, non-standard models. For a more in-depth description of Bayesian methods 
and their application in healthcare see [28]. 
 
3.1 Model development 
As already mentioned above, previous evidence suggests that the EQ-5D score is 
skewed toward the upper bound.  If the EQ-5D utility of observation i is ௜ܻ then we 
define disutility as ܦ௜ ൌ ͳ െ ௜ܻ.  In TPMs, we are interested in first estimating the 
likelihood of ܦ௜ ൌ Ͳ (alternatively ௜ܻ=1) and secondly how large  ܦ௜ in the case it is 
nonzero.  By doing this, TPMs essentially attempt to filter off individuals with zero-
disutility, and then a distribution to the remainder (i.e. to those individuals who have a 
nonzero disutility).   
 
Algebraically, let id  be a dummy variable, which takes value 1 when ܦ௜ ൐ Ͳ and the 
value 0 otherwise. Utility, as our estimated variable of interest, is then calculated based 
on both the likelihood of a nonzero disutility and the expected size of any non-zero 
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disutility. All four models have a common functional form in the first part (Part A), as 
follows: 
 
)(~ ii pBernoullid
 
 iii XXp 2221110 ...][logit DDD  , (1) 
where ip  is the probability of observing a disutility, kiX  indicates values for the k 
covariates for individual i (i.e. 19 QLQ scores plus age and gender) and the kD  
parameters are estimated within the logistic model. In these cases, the vague priors used 
set are as follows   
)10,0(~,..., 6210 NDD . 
To assess the importance of addressing these potential complexities, four different (Part 
B) models are also fitted to estimate disutility when ܦ௜ ൐ Ͳ.   
Model 1: Normally distributed Part B 
For those individuals who have a nonzero disutility, Part B of the model becomes: 
 ),(~)0|( 2VPiii NDD !  
 iii XX 2121110 ... EEEP    (2) 
where iX s indicate observation-specific values for the 21 covariates (i.e. 19 QLQ 
scores, age and gender), and kE ¶VDUH the regression parameters to be estimated. Vague 
prior distributions were specified as follows: 
)10,0(~,... 6210 NEE ,  2V )001.0,001.0(maInverseGam~  
Model 2: Normally distributed Part B with variance a function of age and gender,  
In Model 2, the TPM Model 1 again has a normal conditional distribution but allows 
variance to be a function of participant characteristics. In this model we allowed the 
logarithm of the variance to also be a function of age ( iX20 ) and gender ( iX21 ); that is:  
 
),(~)0|( 2iiii NDD VP!
 
 iii XX 2121110 ... EEEP   
 iii XX 2122010
2 )(Log TTTV   (3) 
 9 
where again kiX s indicate individual values for the 21 covariates and E ¶V DUH WKH
estimated parameters. Prior distributions were specified as: 
)10,0(~,,,,... 6210210 NTTTEE  
Model 3: Lognormally distributed Part B 
In Model 3, the disutility is estimated with a similar equation to Model 1 but assumes 
a lognormal distribution with uniform variance across observations.  Here, Part B is: 
 
),(~)0|( 2VPiii LNDD !
 
 
iii XX 2222110 ... EEEP  
 (4) 
where kiX s indicate observation-specific values for the 21 covariates (i.e. 19 QLQ 
scores, age and gender), and kE s are the regression parameters to be estimated. Vague 
prior distributions were specified as follows: 
)10,0(~,... 6210 NEE ,  2V )001.0,001.0(maInverseGam~  
Model 4: Gamma distributed Part B with a log link. 
The fourth model specified disutility as a Gamma regression with a log link function.  
Here, the log of mean disutilities is modelled as a function of the covariates.  Both the 
mean value by observation ( iP ) and the common variance ( 2V ) are related to the 
parameters of the Gamma distributions ( ii ba ,  ).  (Here, iii ba / P  and 22 / ii ba V ) 
In this model, Part B is: 
),(Gamma~)0|( iiii baDD !
 
 iii ba P  and 2/VPiib   
 iii XX 2121110 ...)log( EEEP   (5) 
As before, the 22 parameters kE  are estimated in the log-linear model and include the 
constant term, 20 QLQ scores, and covariates for age and gender. Prior distributions 
were specified as: 
)10,0(~,... 6210 NEE ,  2V )001.0,001.0(maInverseGam~ . 
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3.2 Model prediction 
To assess the predictive ability of Models 1-4 each was applied to derive utilities for 
both the derivation and validation samples of the cohort of individuals with myeloma. 
The expected deficit in HRQoL is expressed as the expected mean disutility (in the case 
that one is observed in a particular observation) multiplied by the probability of 
observing a nonzero disutility, and is given by the equations (6) - (8) below: 
 
As a similar/common first part appears across the models, we first define the expected 
likelihood of a disutility as: 
)...exp(1
)...exp()0(
110
110
kiki
kiki
ii XX
XX
DPp DDD
DDD

 ! , 
 
Models 1 and 2: 
For the second part of the TPMs in Models 1 and 2, the conditional expectation 
)0|( !ii DDE  from the second stage (2) equals: 
 
),0|(...)0|( 2121110 ! ! iiiiii DEXXDDE HEEE  
In TPMs, this last term is assumed to equal zero in contrast to other approaches, for 
H[DPSOH+HFNPDQ¶V>29] sample selection model. The relative merits of the TPM have 
been the subject of a vigorous debate in the literature [30] and much of the discussion 
focuses on this assumption.  Thus, 
iiii XXDDE 2121110 ...)0|( EEE  ! . 
Note that the unconditional expectation of the dependent variable iD , )( iDE , is given 
by 
)0|().0()0|().0()(   !! iiiiiii DDEDPDDEDPDE . 
Then, since 0)0|(   ii DDE , it follows that  
iiiiiiii pXXDDEDPDE )...()0|().0()( 2121110 EEE  !! . 
Therefore, for Models 1 and 2, predicted health (as one minus disutility) is: 
 iiiii pXXY )...(1 2121110
^ EEE  
 (6) 
Model 3: 
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,Q D VLPLODU ZD\ 0RGHO ¶V ORJQRUPDO IRUPXOD IRU HVWLPDWHG GLVXWLOLW\ \LHOGV an 
expected health of: 
 iiii pXXY ])...[exp(1 2212121110
^ VEEE  
 (7) 
And for Model 4: 
 iiii pXXY )...exp(1 2121110
^ EEE  
 (8) 
 
The performance of all models was compared by calculating the proportion of variance 
they explained in both the derivation and validation samples, using the unadjusted R2  
and adjusted R2 statistics measuring the goodness of fit between the predicted and 
observed values [9,31]. 
 
As the intended purpose of our TPM models is to predict the mean EQ-5D scores based 
on the mean EORTC QLQ C-30/QLQ-MY20 domain scores, we compare the predicted 
versus observed mean EQ-5D scores in the overall validation data set and calculate the 
mean absolute prediction error.  The validity of candidate models is also estimated 
using root mean square error (RMSE) criterion for the mean: 
  2/1
1
2 /)Ö(RMSE ¦   Ti ii TYy     (9) 
where T is the number of observations in the test sample.  
 
Finally, the performance of the models fitted above was also compared by calculating 
the Bayesian Deviance Information Criterion (DIC) [28] which combines measures of 
both model fit and model complexity. It is defined by, 
DPDDIC  

 
where 

D
 is the posterior mean deviance and DP  is a measure of model complexity 
which may be termed the effective number of parameters. The DIC is similar to Akaike 
Information Criterion (AIC) [32] and is interpreted as a Bayesian measure of fit 
penalised for increased model complexity. The minimum DIC denotes the model best 
fitting the data [28].  
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4. Results  
4.1. Study cohort 
The entire study population consisted of 3184 observations (1839 patients); 331 
observations (10%) had the EQ-5D utility weight missing and 252 observations (8%) 
had missing values for at least one component of EORTC QLQ-C30/QLQ-MY20. 
Overall, 510 observations had at least one of EQ-5D, EORTC QLQ-C30/QLQ-MY20 
or demographic data values missing.  The complete case analysis was therefore 
performed on a cohort of 2674 observations (i.e. 3184-510=2674 observations from 
1658 patients); the derivation sample had 2003 observations (1244 patients) and the 
validation sample had 671 observations (414 patients). 
 
Table 1 presents the baseline characteristics of the entire population, the complete case 
cohort, and our validation and derivation set. The mean age of the entire population was 
64.75 years and 59% were males, both of which were in line with the complete case 
cohort and the derivation and validation data sets. The observations with missing values 
typically came from an older and more female sample than the observations without 
missing values.  However, the EQ-5D scores and 19 components of the EORTC QLQ-
C30/QLQ-MY20 produced similar means and interquartile ranges (IQR) across both 
the missing and complete sets. The correlations and > 0.3) between the EORTC 
QLQ-C30/QLQ-MY20 domains and the EQ-5D scores were also explored, and the 
results from the final column of Table 1 showed that only dyspnoea, diarrhoea and body 
image had weak correlations with the EQ-5D scores.  
 
To this end, we consider the design characteristics of both the derivation and validation 
samples. In Table 2 we show the mean and count for the 104 EQ-5D health states 
observed in the derivation sample whereas Table 3 presents the corresponding results 
for the 79 states observed in the validation sample. 72 of the 79 states in the validation 
sample also appeared in the derivation sample, with these states accounting for 99% of 
the validation dataset. This substantial overlap suggests that we should expect 
substantially similar fit between the validation and derivation samples. 
 
4.2. Model estimation 
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For each model, a burn-in of 10000 iterations was allowed to reach convergence. 
Convergence was assessed by examining the Gelman-Rubin convergence statistic for 
two MCMC sequences with different initial values [33]. These were followed by a 
further 20,000 iterations for parameter estimation purposes. 
 
Tables 4 and 5 summarise each the estimated distributions for the parameters (including 
the 19 QLQ coefficients) in terms of mean and associated 95% credible intervals.  Table 
4 presents the model predicting whether or not a person is likely to report full 
health/zero disutility, which is used as the first part of the two part models for Models 
1-42. Of the 19 coefficients on QLQ domains (ߙଵ to ߙଵଽ), 12 have credible intervals 
including 0, with zero disutility associated with higher scores on emotional functioning, 
fatigue, physical functioning, and role functioning, but lower scores on appetite loss, 
disease symptoms and pain. Table 5 presents the equivalent distributions for the various 
Part B models.  In only five GRPDLQVGLGWKHFRHIILFLHQW¶VFUHGLEOH LQWHrvals exclude 
zero in all models; here, higher EQ-5D scores (lower disutility) was associated with 
higher scores for emotional functioning, physical functioning, future perspectives and 
fatigue but lower scores for disease symptoms and pain. The 95% credible intervals for 
age and gender included zero in all four models.  
 
4.3. Model reliability and validation 
Table 6 presents the R2, adjusted R2, mean prediction error statistics and RMSE for each 
model. No model clearly dominates across both derivation and valuation tasks. Models 
1 and 2 (normal Part B with/without variance influenced by age and gender) perform 
best within the derivation dataset under R2/adjusted-R2 criteria, and explain around 70% 
of variation; the best performing model on the validation dataset is the TPM with 
Gamma regression and log link, which explains around 68% of the data. The TPM with 
Gamma regression and log link also provides the best performance based on i) lowest 
root mean squared error within the validation dataset and ii) lowest mean predicted 
error in the two datasets.  Finally, the DIC, used to assess complexity and fit of the 
models to the derivation sample was also explored, and the TPM with second part 
                                               
2
 Models 1-4 were estimated individually as joint Part A and Part B.  However, the IRXUGLIIHUHQW³3Drt 
$´UHJUHVVLRQVOHd to very similar results and each had the same parameter estimates (including estimates 
of standard error) up to 5 decimal places.  Thus, it suffices to just state one.  For completeness, Part A of 
Model 1 was reported in Table 4.  
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lognormal regression was found (Table 7) to provide the best fit to the data (DIC = -
943). The TPM with Gamma regression and log link was also found to provide a good 
fit to the data though (DIC = -890.2). 
 
5. Discussion 
 
The aim of this paper was to enable the estimation of EQ-5D health state values based 
on the EORTC QLQ-C30 data using a Bayesian framework. We have developed a 
series of Bayesian TPM regression models and have found that the TPM model with 
normal regression and the TPM model with normal regression, with variance a function 
of participant characteristics perform best within the derivation dataset under 
R2/adjusted R2 criteria, and explains around 70% of variation; the best performing 
model on the validation dataset was the TPM with Gamma regression and log link, 
which explains around 68% of the data. A key advantage of the TPMs presented here 
is that the zero utility observations are separated from the non-zero utility observations, 
thus removing the need for a transformation before a standard regression model can be 
fitted. If zero disutility and non-zero disutility responses are believed to come from 
different data generating processes it is then possible to explore the determinants of 
these by including different sets of covariates in the two parts of the model. 
 
All four models presented here XVHGµYDJXH¶SULRUGLVWULEXWLRQV and were implemented 
using MCMC methods in the software package WinBUGS. This environment provides 
significant flexibility in model specification as it fits nonstandard models, such as those 
TPM models presented in this paper, in a single modelling framework, and all 
parameter estimation uncertainty is automatically incorporated into the results [34]. 
Furthermore, the DIC for model selection is also available as its computation has been 
coded into WinBUGS. It would have been possible to use Bayes factors instead to 
quantify the relative ability of the four models in predicting the data [35]. However, in 
comparison to DIC, the use of Bayes factors require informative prior distributions, 
which we did not have here. 
 
The Tobit Model is another approach to address data with ceiling effects [36]. This 
approach may be considered more efficient than the TPM unless the normality and 
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homoscedasticity assumptions are violated [37, 38]. It is worth mentioning that Tobit 
model was also fitted to the EORTC QLQ-C30 data (results not shown) and residuals 
were examined against the predictor variables. We have found that the residuals were 
not constant across the level of each predictor and so our data empirically suggest that 
the Tobit model at least violates the assumption of homoscedasticity. Latent Class and 
Heckman sample selection models are also considered alternative approaches to the 
TPM to address data with ceiling effects. However, there is a well-established debate 
in health econometrics over the merits of the latter versus TPM models as of which of 
these works best empirically [39]. 
 
There is a scope for using more complex models such as generalized linear models [40, 
41] and survival-type models to predict utilities. The latter is attractive due to the lack 
of assumptions required regarding the error [14] as well as their potential to cope with 
censored data. It is worth mentioning that implementing such models in an MCMC 
setting and using WinBUGS would be possible. It is perhaps worth mentioning that a 
TPM with second part beta regression was also fitted to the EORTC QLQ-C30 data 
(results not shown but available upon request from the leading author), EXW GLGQ¶W
provide further improvement over the four models presented here. We believe that the 
explanation for this finding is due to only 8% of the patients had EQ-5D scores at the 
ceiling of one. Indeed, in a healthy population, where a substantially higher proportion 
may have been at the ceiling, models such as TPM with second part beta regression or 
even models presented here may have better performance. Additional work includes 
dealing with missing follow-up utility data which, again, could be incorporated and 
implemented in MCMC setting using the Bayesian multiple imputation approach as 
mentioned by Kharroubi et al [42]. 
 
This paper has proposed four alternative TPM models for modelling and predicting 
utilities. Although it is not possible to recommend one particular model for analysing 
utility data in general, due to the specific characteristics of each data set and therefore 
the need for a series of different models to be fitted and model fit assessed, the analyses 
presented have demonstrated how utility data may be straightforwardly modelled using 
Bayesian hierarchical models, and model fit and complexity assessed using the DIC, 
which is straightforward to compute in a MCMC analysis. Such models provide 
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important information for the planning of future services and budgets, and may also be 
used to inform cost-effectiveness analyses. 
 
In conclusion, we found that mean EQ-5D utility weights can be accurately estimated 
using a TPM regression mapping algorithm from the EORTC QLQ-C30/QLQ-MY20. 
Whilst previous models for mapping the EORTC QLQ-C30 to the EQ-5D exist [43, 
44], this is the first model to our knowledge to explicitly consider a myeloma subgroup 
and to include the MY-20 data. Such a model will be of significant use to investigators 
conducting economic evaluations, by generating preference-based utility weights in 
patients with myeloma.   
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Table 1: Baseline Characteristics of Study Cohort (Kharroubi et al [45]). 
Note: PF, physical functioning; RF, role functioning; DY, dyspnoea; PA, pain; FA, fatigue; SL, insomnia; AP, appetite loss; NV, Nausea and vomiting; CO, constipation; DI, 
diarrhoea; CF, cognitive functioning; EF, emotional functioning; SF, social functioning; FI, financial difficulties; QL, quality of life; DS, disease symptoms; SE, side effects; 
%,ERG\LPDJH)3IXWXUHSHUVSHFWLYH1$QRWDSSOLFDEOHȡFRUUHODWLRQFRHIILFLHQW 
  
    Missing Data Complete       
  Entire population EQ-5D QLQ-MY20 Case Cohort Derivation Set Validation Set ʌ 
No of patients 1839 318 240 1658 1244 414   
No of obn 3184 331 252 2674 2003 671   
Age, mean(IQR) 64.75 (58-72) 65.6 (58-73) 67.53 (60-76) 64.45 (58-72)  64.4 (58-72) 64.62 (58-72)   
Male, % 59.22 56.6 55 59.89 59.97 59.66   
EQ-5D, mean(IQR) 0.52(0.26-0.76) NA 0.47(0.19-0.76) 0.52(0.26-0.76) 0.52(0.26-0.76) 0.52(0.26-0.76)   
PF, mean(IQR) 58.05(40-80) 58.11(40-80) NA 58.29(40-80) 58.02(40-80) 58.08(40-80) 0.75 
RF, mean(IQR) 42.16(0-66.67) 41.53(0-66.67) NA 42.40(0-66.67) 42.17(0-66.67) 42.09(0-66.67) 0.68 
DY, mean(IQR) 32.24(0-66.67) 32.43(0-66.67) NA 32.01(0-33.34) 32.10(0-33.34) 31.74(0-66.67) -0.26 
PA, mean(IQR) 44.01(16.67-66.67) 48.26(16.67-83.34) NA 43.46(16.67-66.67) 43.33(16.67-66.67) 43.84(16.67-66.67) -0.70 
FA, mean(IQR) 51.52(33.34-66.67) 51.20(33.34-66.67) NA 51.45(33.34-66.67) 51.34(33.34-66.67) 51.79(33.34-66.67) -0.61 
SL, mean(IQR) 34.77(0-66.67) 35.47(0-66.67) NA 34.60(0-66.67) 34.47(0-66.67) 35.02(0-66.67) -0.35 
AP, mean(IQR) 29.68(0-66.67) 30.73(0-66.67) NA 29.24(0-66.67) 29.51(0-66.67) 28.47(0-33.34) -0.45 
NV, mean(IQR) 13.20(0-16.67) 14.81(0-16.67) NA 12.93(0-16.67) 13.13(0-16.67) 12.34(0-16.67) -0.36 
CO, mean(IQR) 32.41(0-66.67) 35.84(0-66.67) NA 32.11(0-66.67) 31.84(0-66.67) 32.94(0-66.67) -0.39 
DI, mean(IQR) 10.07(0-0) 11.95(0-0) NA 9.81(0-0) 10.18(0-0) 8.70(0-0) -0.10 
CF, mean(IQR) 73.10(50-100) 72.53(50-100) NA 73.22(66.67-100) 73.13(66.67-100) 73.50(66.67-100) 0.48 
EF, mean(IQR) 70.24(58.34-91.67) 70.09(55.56-91.67) NA 70.38(58.34-91.67) 70.51(58.34-91.67) 70.00(58.34-91.67) 0.51 
SF, mean(IQR) 50.11(16.67-83.34) 50.86(16.67-83.34) NA 50.09(16.67-83.34) 50.08(16.67-83.34) 50.10(16.67-83.34) 0.64 
FI, mean(IQR) 20.54(0-33.34) 19.51(0-33.34) NA 20.61(0-33.34) 21.32(0-33.34) 18.48(0-33.34) -0.30 
QL, mean(IQR) 51.15(33.34-66.67) 48.93(33.34-66.67) NA 51.53(33.34-66.67) 51.46(33.34-66.67) 51.71(33.34-66.67) 0.64 
DS, mean(IQR) 31.91(13.34-50) 34.18(16.67-50) NA 31.59(11.12-46.67) 32.04(11.12-50) 30.22(13.34-44.45) -0.62 
SE, mean(IQR) 23.77(11.12-33.34) 24.15(11.12-33.34) NA 23.66(11.12-33.34) 23.57(11.12-33.34) 23.93(11.12-33.34) -0.51 
BI, mean(IQR) 70.98(33.34-100) 73.15(66.67-100) NA 71.09(33.34-100) 71.72(33.34-100) 67.20(33.34-100) 0.28 
FP, mean(IQR) 48.16(33.34-66.67) 46.71(22.23-66.67) NA 48.33(33.34-66.67) 48.95(33.34-66.67) 45.49(22.23-66.67) 0.35 
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Table 2: Mean and count for 104 health states in the derivation sample 
State Mean n State Mean n State Mean n State Mean n 
11111 1 169 12232 0.053 1 21332 0.03 7 23322 0.079 8 
11112 0.848 62 12311 0.452 1 21333 -0.135 2 23323 -0.086 1 
11113 0.414 3 12321 0.329 3 22111 0.746 1 23332 -0.184 8 
11121 0.796 88 12322 0.258 2 22132 0.02 1 23333 -0.349 4 
11122 0.725 57 12331 0.066 1 22211 0.71 9 31311 0.242 2 
11123 0.291 1 12332 -0.005 3 22212 0.639 9 31312 0.171 1 
11211 0.883 55 21111 0.85 21 22213 0.205 1 31322 0.048 1 
11212 0.812 21 21112 0.779 10 22221 0.587 64 31323 -0.117 1 
11221 0.76 115 21121 0.727 34 22222 0.516 117 32131 -0.154 1 
11222 0.689 68 21122 0.656 12 22223 0.082 10 32222 0.002 1 
11223 0.255 8 21131 0.195 3 22231 0.055 20 32311 0.138 5 
11232 0.157 4 21211 0.814 38 22232 -0.016 39 32312 0.067 2 
11311 0.556 4 21212 0.743 22 22233 -0.181 7 32313 -0.098 1 
11312 0.485 2 21221 0.691 164 22311 0.383 9 32321 0.015 1 
11321 0.433 14 21222 0.62 145 22312 0.312 9 32322 -0.056 10 
11322 0.362 11 21223 0.186 8 22313 0.147 3 32323 -0.221 1 
11323 0.197 1 21231 0.159 18 22321 0.26 48 32331 -0.248 1 
11331 0.17 1 21232 0.088 28 22322 0.189 119 32332 -0.319 5 
11332 0.099 2 21233 -0.077 1 22323 0.024 7 32333 -0.484 3 
11333 -0.066 2 21311 0.487 12 22331 -0.003 22 33311 0.028 2 
12112 0.744 1 21312 0.416 8 22332 -0.074 61 33312 -0.043 1 
12132 0.089 1 21313 0.251 2 22333 -0.239 9 33321 -0.095 2 
12213 0.274 1 21321 0.364 31 23222 0.137 1 33322 -0.166 4 
12221 0.656 7 21322 0.293 45 23231 -0.055 1 33331 -0.358 3 
12222 0.585 10 21323 0.128 5 23311 0.273 1 33332 -0.429 14 
12231 0.124 2 21331 0.101 6 23321 0.15 2 33333 -0.594 7 
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Table 3: Mean and count for 79 health states in the validation sample 
State Mean n State Mean N State Mean n 
11111 1 51 21132 0.124 1 22313 0.147 1 
11112 0.848 21 21211 0.814 16 22321 0.26 13 
11121 0.796 30 21212 0.743 8 22322 0.189 38 
11122 0.725 18 21221 0.691 51 22323 0.024 5 
11131 0.264 2 21222 0.62 54 22331 -0.003 4 
11211 0.883 20 21223 0.186 3 22332 -0.074 19 
11212 0.812 16 21231 0.159 8 22333 -0.239 2 
11213 0.378 1 21232 0.088 5 23222 0.137 3 
11221 0.76 28 21233 -0.077 1 23311 0.273 1 
11222 0.689 24 21311 0.487 4 23321 0.15 1 
11223 0.255 4 21312 0.416 3 23322 0.079 6 
11311 0.556 2 21321 0.364 9 23323 -0.086 1 
11312 0.485 1 21322 0.293 13 23332 -0.184 3 
11321 0.433 5 21323 0.128 2 31322 0.048 1 
11322 0.362 3 21331 0.101 3 32313 -0.098 1 
12212 0.708 2 21332 0.03 5 32321 0.015 1 
12221 0.656 4 22121 0.623 1 32322 -0.056 2 
12222 0.585 2 22211 0.71 3 32331 -0.248 2 
12312 0.381 1 22212 0.639 3 32332 -0.319 4 
12321 0.329 1 22221 0.587 32 32333 -0.484 3 
12322 0.258 1 22222 0.516 50 33311 0.028 1 
12332 -0.005 1 22223 0.082 1 33321 -0.095 1 
13322 0.148 1 22231 0.055 4 33322 -0.166 2 
21111 0.85 2 22232 -0.016 9 33332 -0.429 5 
21112 0.779 1 22233 -0.181 2 33333 -0.594 1 
21121 0.727 7 22311 0.383 1    
21122 0.656 8 22312 0.312 1    
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Table 4: Results of first part of Models 1-- 4 
 QLQ domain* Coefficient (credible interval) ߙ଴ (Constant)  15.65 (11.54, 20.10) ߙଵ Appetite Loss 2.233 (0.766, 3.820) ߙଶ Body Image -0.172 (-1.205, 0.881) ߙଷ Cognitive Functioning 1.124 (-0.729, 2.810) ߙସ Constipation -0.292 (-1.268, 0.701) ߙହ Diarrhoea 1.253 (-0.357, 2.958) ߙ଺ Disease Symptoms 4.934 (2.235, 7.739) ߙ଻ Dyspnoea -0.332 (-1.485, 0.798) ߙ଼ Emotional Functioning -6.648 (-9.105, -4.415) ߙଽ Fatigue -2.105 (-4.017, -0.209) ߙଵ଴ Financial Difficulties 1.145 (-0.204, 2.594) ߙଵଵ Future Perspective -0.664 (-1.818, 0.463) ߙଵଶ Nausea and Vomitingg -0.013 (-2.846, 2.908) ߙଵଷ Pain 5.874 (3.645, 8.201) ߙଵସ Physical Functioning -6.703 (-9.398, -4.095) ߙଵହ Quality of Life -1.706 (-3.563, 0.138) ߙଵ଺ Role Functioning -2.929 (-4.529, -1.251) ߙଵ଻ Side Effects -0.544 (-3.521, 2.503) ߙଵ଼ Social Functioning 0.063 (-1.477, 1.592) ߙଵଽ Insomnia/Sleep -0.628 (-1.708, 0.471) ߙଶ଴ (age)  -0.009 (-0.034, 0.0142) ߙଶଵ (female)  -0.202 (-0.740, 0.316) 
Note: (*) All variables are included as 100x standard QLQ domains. Values given as posterior mean (central 95% credible interval). Estimates shown in bold are those who 
have credible intervals excluding zero.  
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Table 5: Results of second part models (Models 1-- 4) 
 
QLQ* Model 1 Model 2 Model 3 Model 4 ߚ଴ (Constant)  0.885 (0.793, 0.972) 0.876 (0.782, 0.961) -0.221 (-0.392, -0.047) -0.223 (-0.374, -0.050) ߚଵ AP 0.051 (0.017, 0.086) 0.053 (0.018, 0.086) 0.066 (-0.001, 0.134) 0.076 (0.013, 0.144) ߚଶ BI 0.023 (-0.005, 0.052) 0.024 (-0.005, 0.053) 0.048 (-0.008, 0.104) 0.040 (-0.023, 0.094) ߚଷ CF 0.017 (-0.031, 0.064) 0.014 (-0.033, 0.060) 0.078 (-0.016, 0.170) 0.106 (0.031, 0.182) ߚସ CO 0.015 (-0.014, 0.044) 0.016 (-0.013, 0.045) 0.000 (-0.057, 0.057) 0.006 (-0.057, 0.054) ߚହ DI -0.054 (-0.097, -0.011) -0.058 (-0.101, -0.016) -0.077 (-0.161, 0.006) -0.091 (-0.176, -0.011) ߚ଺ DS 0.124 (0.062, 0.185) 0.129 (0.067, 0.190) 0.208 (0.090, 0.328) 0.189 (0.072, 0.303) ߚ଻ DY -0.038 (-0.071, -0.006) -0.037 (-0.069, -0.005) -0.045 (-0.107, 0.018) -0.050 (-0.106, 0.014) ߚ଼ EF -0.145 (-0.197, -0.092) -0.144 (-0.199, -0.091) -0.241 (-0.346, -0.137) -0.266 (-0.378, -0.168) ߚଽ FA -0.088 (-0.147, -0.027) -0.085 (-0.144, -0.025) -0.144 (-0.261, -0.026) -0.121 (-0.231, -0.011) ߚଵ଴ FI 0.002 (-0.029, 0.033) 0.002 (-0.028, 0.031) 0.053 (-0.007, 0.113) 0.038 (-0.020, 0.095) ߚଵଵ FP -0.073 (-0.115, -0.031) -0.071 (-0.112, -0.029) -0.144 (-0.226, -0.059) -0.136 (-0.223, -0.070) ߚଵଶ NV 0.020 (-0.032, 0.071) 0.020 (-0.031, 0.072) 0.041 (-0.061, 0.143) 0.042 (-0.056, 0.140) ߚଵଷ PA 0.218 (0.171, 0.265) 0.217 (0.171, 0.264) 0.463 (0.370, 0.553) 0.463 (0.375, 0.557) ߚଵସ PF -0.510 (-0.568, -0.452) -0.515 (-0.571, -0.457) -0.955 (-1.066, -0.843) -0.820 (-0.909, -0.718) ߚଵହ QF -0.090 (-0.153, -0.025) -0.081 (-0.142, -0.020) -0.117 (-0.237, 0.001) -0.119 (-0.236, 0.013) ߚଵ଺ RF -0.038 (-0.086, 0.011) -0.034 (-0.083, 0.014) -0.200 (-0.294, -0.105) -0.257 (-0.337, -0.173) ߚଵ଻ SE 0.086 (0.002, 0.172) 0.092 (0.011, 0.175) 0.113 (-0.053, 0.271) 0.141 (-0.033, 0.313) ߚଵ଼ SF -0.055 (-0.100, -0.012) -0.056 (-0.101, -0.011) -0.129 (-0.214, -0.044) -0.139 (-0.214, -0.069) ߚଵଽ SL 0.009 (-0.022, 0.040) 0.008 (-0.022, 0.039) 0.013 (-0.046, 0.074) 0.012 (-0.046, 0.069) ߚଶ଴ (age)  0.000 (-0.001, 0.001) 0.000 (-0.001, 0.001) 0.000 (-0.002, 0.002) 0.001 (-0.001, 0.003) ߚଶଵ (female)  -0.015 (-0.034, 0.04) -0.014 (-0.033, 0.005) -0.015 (-0.053, 0.021) -0.007 (-0.042, 0.030) ߪ  0.191 (0.184, 0.197) NA 0.372 (0.360, 0.384) 0.189 (0.184, 0.197) ߠ (Constant)  NA 3.438 (3.241, 3.633) NA NA ߠଵ (age)  NA -0.009 (-0.016, -0.003) NA NA ߠଶ (female)  NA -0.084 (-0.217, 0.047) NA NA 
Note: PF, physical functioning; RF, role functioning; DY, dyspnoea; PA, pain; FA, fatigue; SL, insomnia; AP, appetite loss; NV, Nausea and vomiting; CO, constipation; DI, diarrhoea; CF, 
cognitive functioning; EF, emotional functioning; SF, social functioning; FI, financial difficulties; QL, quality of life; DS, disease symptoms; SE, side effects; BI, body image; FP, future 
perspective; NA, not applicable; (*) All variables are included as 100x standard QLQ domains. Values given as posterior mean (central 95% credible interval). Estimates shown in bold are those 
who have credible intervals excluding zero.  
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Table 6: Model performance based on central estimate 
 
Derivation data set Validation data set 
 
R2 Adjusted R2 Mean predicted 
error 
R2 Adjusted R2 Mean predicted 
error 
RMSE 
Model 1 0.7005 0.6940 0.1431 0.6787 0.6572 0.1471 0.1892 
Model 2 0.7005 0.6937 0.1430 0.6778 0.6552 0.1472 0.1894 
Model 3 0.6864 0.6797 0.1463 0.6714 0.6494 0.1466 0.1913 
Model 4 0.6959 0.6893 0.1387 0.6803 0.6589 0.1394 0.1887 
Note: R2, proportion of variance explained by the model; Estimates shown in bold are best performing models. 
 
 
 
Table 7: Overall DIC for the fitted models 
 
Model 1 Model 2 Model 3 Model 4 

D
 
-337.6 -345.0 -988.2 -934.6 
DP  44.76 46.53 45.20 44.46 
DIC -292.8 -298.5 -943.0 -890.2 
 
 
